TLDR Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
The document reported a case of severe refractory scarring alopecia linked to the combined use of Ficlatuzumab (AV-299) and Gefitinib. The authors, Yi-Hsien Shih, Pin-Chun Chen, and Chia-Yu Chu, highlighted the potential adverse effects of this drug combination, emphasizing the need for careful monitoring in patients undergoing such treatments. The study underscored the importance of recognizing drug-induced alopecia as a significant side effect, which could impact patient quality of life and treatment adherence.
25 citations,
April 2010 in “Clinical and Experimental Dermatology” Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
73 citations,
November 2000 in “Proceedings of the National Academy of Sciences of the United States of America” There are two ways to start hair growth: one needs Stat3 and the other does not, but both need PI3K activation.
1 citations,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
179 citations,
June 2000 in “The American journal of pathology” The absence of functional sebaceous glands causes hair follicle destruction and scarring alopecia.
54 citations,
January 2009 in “British Journal of Dermatology” Scarring alopecia affects different hair follicle stem cells than nonscarring alopecia, and the infundibular region could be a new treatment target.
37 citations,
June 2011 in “Journal of The American Academy of Dermatology” Loss of sebaceous glands and inflammation may contribute to the development of scarring alopecia.
29 citations,
July 2008 in “Journal of Cutaneous Pathology” Hair root sheaths are more common in non-scarring hair loss and help diagnose the type of hair loss.
